Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout

Longer-Lasting Toxin May Have Advantage In Cervical Dystonia

Similar to its post-approval strategy in aesthetics less than a year ago, Revance will initially target a small number of doctors as it Daxxify to market in the US for cervical dystonia with a broader launch in 2024.

Woman having Neck and Shoulder pain — In cervical dystonia, neck muscles contract involuntarily • Source: Shutterstock

Revance Therapeutics, Inc. has won US Food and Drug Administration for Daxxify (daxibotulinumtoxinA-lanm) in the treatment of cervical dystonia (CD) – its second indication overall, but its first therapeutic use. The product, initially approved as an aesthetic medicine to reduce the appearance of glabellar lines, has the potential to best market leader Botox (onabotulinumtoxinA) in CD given its longer-lasting efficacy in a disease where neuromodulator benefits often wear off too soon for retreatment.

Nashville, TN-based Revance announced the FDA approval in CD on 14 August, 11 months after its first approval for glabellar lines (frown lines between the eyes) in September 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.